ES2238076T3 - Composiciones y procedimientos para matrices extracelulares secretadas de forma natural. - Google Patents
Composiciones y procedimientos para matrices extracelulares secretadas de forma natural.Info
- Publication number
- ES2238076T3 ES2238076T3 ES96921369T ES96921369T ES2238076T3 ES 2238076 T3 ES2238076 T3 ES 2238076T3 ES 96921369 T ES96921369 T ES 96921369T ES 96921369 T ES96921369 T ES 96921369T ES 2238076 T3 ES2238076 T3 ES 2238076T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- extracellular matrix
- collagen
- dimensional
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000002744 extracellular matrix Anatomy 0.000 title claims abstract description 75
- 238000000034 method Methods 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title abstract description 27
- 210000004027 cell Anatomy 0.000 claims abstract description 121
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 79
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 79
- 210000001519 tissue Anatomy 0.000 claims abstract description 74
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 210000002950 fibroblast Anatomy 0.000 claims description 43
- 239000000463 material Substances 0.000 claims description 40
- 230000012010 growth Effects 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- -1 polypropylene Polymers 0.000 claims description 9
- 238000004113 cell culture Methods 0.000 claims description 8
- 210000002889 endothelial cell Anatomy 0.000 claims description 7
- 210000001612 chondrocyte Anatomy 0.000 claims description 5
- 229920000954 Polyglycolide Polymers 0.000 claims description 4
- 239000004793 Polystyrene Substances 0.000 claims description 4
- 239000004633 polyglycolic acid Substances 0.000 claims description 4
- 229920002223 polystyrene Polymers 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 229920000742 Cotton Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000000020 Nitrocellulose Substances 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 239000002729 catgut Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000002349 favourable effect Effects 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 229920001220 nitrocellulos Polymers 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims 1
- 210000004416 odontoblast Anatomy 0.000 claims 1
- 210000000963 osteoblast Anatomy 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
- 239000003356 suture material Substances 0.000 claims 1
- 230000002950 deficient Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 102000008186 Collagen Human genes 0.000 description 80
- 108010035532 Collagen Proteins 0.000 description 80
- 229920001436 collagen Polymers 0.000 description 80
- 210000002536 stromal cell Anatomy 0.000 description 38
- 239000011159 matrix material Substances 0.000 description 35
- 238000002360 preparation method Methods 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 20
- 239000002609 medium Substances 0.000 description 19
- 239000007943 implant Substances 0.000 description 18
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 241000283690 Bos taurus Species 0.000 description 17
- 230000007547 defect Effects 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 239000003102 growth factor Substances 0.000 description 13
- 230000002500 effect on skin Effects 0.000 description 12
- 229920001778 nylon Polymers 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000004677 Nylon Substances 0.000 description 11
- 229920002683 Glycosaminoglycan Polymers 0.000 description 10
- 239000000835 fiber Substances 0.000 description 10
- 210000004872 soft tissue Anatomy 0.000 description 10
- 239000002245 particle Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000003599 detergent Substances 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 230000008439 repair process Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 102000016359 Fibronectins Human genes 0.000 description 7
- 108010067306 Fibronectins Proteins 0.000 description 7
- 108090000631 Trypsin Proteins 0.000 description 7
- 102000004142 Trypsin Human genes 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 239000000314 lubricant Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000002356 single layer Substances 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- 229960001322 trypsin Drugs 0.000 description 7
- 102000012422 Collagen Type I Human genes 0.000 description 6
- 108010022452 Collagen Type I Proteins 0.000 description 6
- 108060003393 Granulin Proteins 0.000 description 6
- 102000013373 fibrillar collagen Human genes 0.000 description 6
- 108060002894 fibrillar collagen Proteins 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 230000003416 augmentation Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000000501 collagen implant Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 102000007000 Tenascin Human genes 0.000 description 4
- 108010008125 Tenascin Proteins 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 102000004237 Decorin Human genes 0.000 description 3
- 108090000738 Decorin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010039918 Polylysine Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000013020 final formulation Substances 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 210000003254 palate Anatomy 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010049070 Breast hypoplasia Diseases 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 2
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000030944 contact inhibition Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003630 growth substance Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000003668 pericyte Anatomy 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 208000002021 Enophthalmos Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000002325 Funnel Chest Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010061199 Head deformity Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 206010034204 Pectus excavatum Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 208000019222 Poland syndrome Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 208000006812 Velopharyngeal Insufficiency Diseases 0.000 description 1
- 206010066790 Velopharyngeal incompetence Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000005248 Vocal Cord Paralysis Diseases 0.000 description 1
- 241000219995 Wisteria Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001587 cholestatic effect Effects 0.000 description 1
- 229940094517 chondroitin 4-sulfate Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000515 collagen sponge Substances 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000002980 facial hemiatrophy Diseases 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 208000016809 linear scleroderma Diseases 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 210000001724 microfibril Anatomy 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004788 neurological cell Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000031055 positive regulation of mitosis Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000037309 reepithelialization Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000001590 sorbitan monolaureate Substances 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0059—Cosmetic or alloplastic implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/10—Hair or skin implants
- A61F2/105—Skin implants, e.g. artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/470,101 US5830708A (en) | 1995-06-06 | 1995-06-06 | Methods for production of a naturally secreted extracellular matrix |
| US470101 | 1995-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2238076T3 true ES2238076T3 (es) | 2005-08-16 |
Family
ID=23866272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES96921369T Expired - Lifetime ES2238076T3 (es) | 1995-06-06 | 1996-06-06 | Composiciones y procedimientos para matrices extracelulares secretadas de forma natural. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5830708A (enExample) |
| EP (1) | EP0967934B1 (enExample) |
| JP (1) | JP3709487B2 (enExample) |
| KR (1) | KR19990022216A (enExample) |
| AT (1) | ATE290350T1 (enExample) |
| AU (1) | AU708090B2 (enExample) |
| CA (1) | CA2223892A1 (enExample) |
| DE (1) | DE69634454T2 (enExample) |
| ES (1) | ES2238076T3 (enExample) |
| NZ (1) | NZ311313A (enExample) |
| WO (1) | WO1996039101A1 (enExample) |
Families Citing this family (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6974571B2 (en) * | 1995-03-28 | 2005-12-13 | Thomas Jefferson University | Isolated stromal cells and methods of using the same |
| US6284284B1 (en) | 1995-06-06 | 2001-09-04 | Advanced Tissue Sciences, Inc. | Compositions and methods for production and use of an injectable naturally secreted extracellular matrix |
| US7767452B2 (en) | 1997-02-20 | 2010-08-03 | Kleinsek Don A | Tissue treatments with adipocyte cells |
| AU6661698A (en) * | 1997-02-20 | 1998-09-09 | Gregory S. Keller | Augmentation and repair of dermal, subcutaneous, and vocal cord tissue defects |
| US6225118B1 (en) | 1997-10-01 | 2001-05-01 | Biocure Limited | Multicellular in vitro assay of angiogenesis |
| GB9720987D0 (en) * | 1997-10-01 | 1997-12-03 | Biocure Ltd | A multicellular in vitro assay of angiogenesis |
| US6660301B1 (en) * | 1998-03-06 | 2003-12-09 | Biosphere Medical, Inc. | Injectable microspheres for dermal augmentation and tissue bulking |
| WO1999047186A1 (en) * | 1998-03-18 | 1999-09-23 | University Of Pittsburgh | Chitosan-based composite materials containing glycosaminoglycan for cartilage repair |
| US6378527B1 (en) * | 1998-04-08 | 2002-04-30 | Chondros, Inc. | Cell-culture and polymer constructs |
| US6428978B1 (en) * | 1998-05-08 | 2002-08-06 | Cohesion Technologies, Inc. | Methods for the production of gelatin and full-length triple helical collagen in recombinant cells |
| ATE305967T1 (de) * | 1998-11-19 | 2005-10-15 | Organogenesis Inc | Biotechnisch konstruiertes gewebe und verfahren zu dessen produktion und benutzung |
| US7615373B2 (en) | 1999-02-25 | 2009-11-10 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen and tissue engineering |
| US6662805B2 (en) | 1999-03-24 | 2003-12-16 | The Johns Hopkins University | Method for composite cell-based implants |
| US20030007954A1 (en) | 1999-04-12 | 2003-01-09 | Gail K. Naughton | Methods for using a three-dimensional stromal tissue to promote angiogenesis |
| US6372494B1 (en) | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
| EP1196206A1 (en) * | 1999-07-09 | 2002-04-17 | Advanced Tissue Sciences, Inc. | Human naturally secreted extracellular matrix-coated device |
| AU7067200A (en) * | 1999-08-23 | 2001-03-19 | Organogenesis Inc. | Skin care compositions and treatments |
| WO2001032129A2 (en) * | 1999-11-05 | 2001-05-10 | Gerigene Medical Corporation | Augmentation and repair of age-related soft tissue defects |
| US7799325B2 (en) * | 1999-11-05 | 2010-09-21 | Kleinsek Donald A | Removal of hypertrophic scars |
| US20080286242A2 (en) * | 1999-11-05 | 2008-11-20 | Donald Kleinsek | Augmentation and repair of spincter defects with cells including mesenchymal cells |
| US20090074729A2 (en) * | 1999-11-05 | 2009-03-19 | Donald Kleinsek | Augmentation and repair of spincter defects with cells including fibroblasts |
| US20080267923A2 (en) * | 1999-11-05 | 2008-10-30 | Donald Kleinsek | Hair undifferentiated cells |
| AU2001250018A1 (en) | 2000-03-02 | 2001-09-12 | University Of Rochester | Ex vivo generation of functional leukemia cells in a three-dimensional bioreactor |
| US6436424B1 (en) * | 2000-03-20 | 2002-08-20 | Biosphere Medical, Inc. | Injectable and swellable microspheres for dermal augmentation |
| WO2001070289A2 (en) | 2000-03-20 | 2001-09-27 | Biosphere Medical, Inc. | Injectable and swellable microspheres for tissue bulking |
| US7338657B2 (en) * | 2001-03-15 | 2008-03-04 | Biosphere Medical, Inc. | Injectable microspheres for tissue construction |
| WO2001070290A2 (en) | 2000-03-20 | 2001-09-27 | Biosphere Medical, Inc. | Injectable microspheres for tissue construction |
| US6638312B2 (en) | 2000-08-04 | 2003-10-28 | Depuy Orthopaedics, Inc. | Reinforced small intestinal submucosa (SIS) |
| US8366787B2 (en) * | 2000-08-04 | 2013-02-05 | Depuy Products, Inc. | Hybrid biologic-synthetic bioabsorbable scaffolds |
| AU2001284968B2 (en) * | 2000-08-16 | 2006-12-21 | Duke University | Decellularized tissue engineered constructs and tissues |
| AU2001288692A1 (en) | 2000-09-01 | 2002-03-13 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed fibrin-based matrices and tissues |
| US20090130066A1 (en) * | 2000-11-06 | 2009-05-21 | Gerigene Medical Corporation | Augmentation and repair of sphincter defects with cells including muscle cells |
| EP1982735A1 (en) * | 2000-11-17 | 2008-10-22 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen |
| US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
| WO2002046373A1 (en) | 2000-12-06 | 2002-06-13 | Hariri Robert J | Method of collecting placental stem cells |
| US7041868B2 (en) | 2000-12-29 | 2006-05-09 | Kimberly-Clark Worldwide, Inc. | Bioabsorbable wound dressing |
| NZ527849A (en) | 2001-02-14 | 2006-09-29 | Anthrogenesis Corp | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| NZ528035A (en) | 2001-02-14 | 2005-07-29 | Robert J Hariri | Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells |
| US20030032961A1 (en) * | 2001-07-16 | 2003-02-13 | Pelo Mark Joseph | Devices from naturally occurring biologically derived materials |
| WO2003007790A2 (en) | 2001-07-16 | 2003-01-30 | Depuy Products, Inc. | Hybrid biologic/synthetic porous extracellular matrix scaffolds |
| JP4302515B2 (ja) | 2001-07-16 | 2009-07-29 | デピュイ・プロダクツ・インコーポレイテッド | 単体型外科装置および方法 |
| US7819918B2 (en) * | 2001-07-16 | 2010-10-26 | Depuy Products, Inc. | Implantable tissue repair device |
| AU2002354911B2 (en) | 2001-07-16 | 2007-08-30 | Depuy Products, Inc. | Meniscus regeneration device and method |
| WO2003007786A2 (en) | 2001-07-16 | 2003-01-30 | Depuy Products, Inc. | Porous delivery scaffold and method |
| US8025896B2 (en) | 2001-07-16 | 2011-09-27 | Depuy Products, Inc. | Porous extracellular matrix scaffold and method |
| WO2003007879A2 (en) * | 2001-07-16 | 2003-01-30 | Depuy Products, Inc. | Cartilage repair and regeneration scaffold and method |
| EP1416880B1 (en) * | 2001-07-16 | 2011-03-02 | DePuy Products, Inc. | Cartilage repair apparatus |
| NZ579705A (en) | 2002-02-13 | 2011-07-29 | Anthrogenesis Corp | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
| AU2003219830A1 (en) * | 2002-02-22 | 2003-09-09 | Ebi, L.P. | Methods and compositions for treating bone or cartilage defects |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| KR100527623B1 (ko) * | 2002-06-01 | 2005-11-15 | 라이프코드인터내셔날 주식회사 | 세포외기질을 포함하는 인공장기 제조용 생분해성 고분자기질 및 그의 제조방법 |
| WO2004047770A2 (en) | 2002-11-26 | 2004-06-10 | Anthrogenesis Corporation | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
| IL156945A0 (en) * | 2003-07-15 | 2004-02-08 | Itzhak Tavori | Device and a method for orthopedic delivery of bone reconstruction medium |
| US7326571B2 (en) * | 2003-07-17 | 2008-02-05 | Boston Scientific Scimed, Inc. | Decellularized bone marrow extracellular matrix |
| JP2005211099A (ja) * | 2004-01-27 | 2005-08-11 | Olympus Corp | 人工臓器構成材および人工臓器構成体の製造方法および人工臓器 |
| US7569233B2 (en) | 2004-05-04 | 2009-08-04 | Depuy Products, Inc. | Hybrid biologic-synthetic bioabsorbable scaffolds |
| WO2005110050A2 (en) * | 2004-05-11 | 2005-11-24 | Synthasome Inc. | Tissue scaffold |
| US20070190108A1 (en) * | 2004-05-17 | 2007-08-16 | Arindam Datta | High performance reticulated elastomeric matrix preparation, properties, reinforcement, and use in surgical devices, tissue augmentation and/or tissue repair |
| AU2005279878A1 (en) * | 2004-08-30 | 2006-03-09 | Theregen, Inc. | Conditioned medium comprising Wnt proteins to promote repair of damaged tissue |
| US7513866B2 (en) | 2004-10-29 | 2009-04-07 | Depuy Products, Inc. | Intestine processing device and associated method |
| US7354627B2 (en) | 2004-12-22 | 2008-04-08 | Depuy Products, Inc. | Method for organizing the assembly of collagen fibers and compositions formed therefrom |
| JP2008546686A (ja) * | 2005-06-17 | 2008-12-25 | セレゲン，インコーポレーテッド | 虚血組織の治療方法 |
| US7595062B2 (en) | 2005-07-28 | 2009-09-29 | Depuy Products, Inc. | Joint resurfacing orthopaedic implant and associated method |
| US20070065415A1 (en) * | 2005-09-16 | 2007-03-22 | Kleinsek Donald A | Compositions and methods for the augmentation and repair of defects in tissue |
| NZ597304A (en) | 2005-10-13 | 2013-06-28 | Anthrogenesis Corp | Immunomodulation using placental stem cells |
| JP5409009B2 (ja) * | 2005-12-01 | 2014-02-05 | エイジェンシー フォー サイエンス，テクノロジー アンド リサーチ | 組織工学の足場としての三次元再構成細胞外マトリクス |
| JP2009521930A (ja) | 2005-12-29 | 2009-06-11 | アントフロゲネシス コーポレーション | 胎盤幹細胞及び第２供給源由来幹細胞の共存培養 |
| DK2471904T3 (en) | 2005-12-29 | 2019-02-18 | Celularity Inc | Placenta stem cell populations |
| US20070178137A1 (en) * | 2006-02-01 | 2007-08-02 | Toby Freyman | Local control of inflammation |
| CA2850793A1 (en) | 2006-10-23 | 2008-05-02 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
| US7871440B2 (en) | 2006-12-11 | 2011-01-18 | Depuy Products, Inc. | Unitary surgical device and method |
| HRP20130765T1 (hr) | 2007-02-12 | 2013-10-25 | Anthrogenesis Corporation | Lijeäśenje protuupalnih bolesti putem matiäśnih stanica posteljice |
| CN101688177A (zh) | 2007-02-12 | 2010-03-31 | 人类起源公司 | 来自贴壁胎盘干细胞的肝细胞和软骨细胞；以及cd34+、cd45-胎盘干细胞富集的细胞群 |
| US9200253B1 (en) | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
| AU2008307633C1 (en) | 2007-09-28 | 2015-04-30 | Celularity Inc. | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
| KR20210056449A (ko) | 2007-11-07 | 2021-05-18 | 안트로제네시스 코포레이션 | 조산 합병증의 치료에 있어서의 제대혈의 용도 |
| CA2692765C (en) | 2007-11-30 | 2015-09-22 | Rnl Bio Co., Ltd | Cellular therapeutic agent for incontinence of urine comprising stem cells originated from decidua or adipose |
| US10702554B2 (en) * | 2007-12-03 | 2020-07-07 | Sanbio, Inc. | Extracellular matrix from pluripotent cells |
| SG10201500237TA (en) | 2008-01-30 | 2015-04-29 | Histogen Inc | Extracellular matrix compositions |
| ES2668398T3 (es) * | 2008-07-02 | 2018-05-17 | Allergan, Inc. | Composiciones y procedimientos para el relleno y la regeneración de tejidos |
| MX339624B (es) | 2008-08-20 | 2016-06-02 | Anthrogenesis Corp | Composiciones mejoradas de celulas y metodos para preparar las mismas. |
| US8852637B2 (en) * | 2008-11-14 | 2014-10-07 | Histogen, Inc. | Extracellular matrix compositions for the treatment of cancer |
| CA2743566C (en) | 2008-11-19 | 2021-11-09 | Anthrogenesis Corporation | Amnion derived adherent cells |
| PL2451964T3 (pl) | 2009-07-10 | 2018-08-31 | Histogen, Inc. | Kompozycje kondycjonowanego podłoża i macierzy zewnątrzkomórkowej z komórek hodowanych w warunkach hipoksji |
| WO2011084925A2 (en) | 2010-01-05 | 2011-07-14 | Cell Constructs, Inc. | Biomaterials made from human hair |
| DK3284818T3 (da) | 2010-01-26 | 2022-06-20 | Celularity Inc | Behandling af knoglerelateret kræft ved hjælp af placenta stamceller |
| TW201703777A (zh) | 2010-04-07 | 2017-02-01 | 安瑟吉納西斯公司 | 利用胎盤幹細胞之血管新生 |
| WO2012009422A1 (en) | 2010-07-13 | 2012-01-19 | Anthrogenesis Corporation | Methods of generating natural killer cells |
| KR20190086482A (ko) | 2010-11-12 | 2019-07-22 | 알러간, 인코포레이티드 | 물질대사된 조건화 성장 배지 및 이용 방법 |
| WO2012092458A2 (en) | 2010-12-30 | 2012-07-05 | Anthrogenesis Corporation | Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof |
| AR084753A1 (es) | 2010-12-30 | 2013-06-05 | Anthrogenesis Corp | Composiciones que comprenden celulas adherentes derivadas del saco amniotico (amdac) y plasma rico en plaquetas (prp) |
| AR093183A1 (es) | 2010-12-31 | 2015-05-27 | Anthrogenesis Corp | Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras |
| DK3011936T3 (da) | 2011-01-06 | 2019-05-20 | Humacyte | Vævsmanipulerede konstrukter |
| CN104220081A (zh) | 2011-06-01 | 2014-12-17 | 人类起源公司 | 利用胎盘干细胞治疗疼痛 |
| JP2014531908A (ja) | 2011-10-14 | 2014-12-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 構造アッセンブリによる配列決定 |
| ES2991004T3 (es) | 2011-12-22 | 2024-12-02 | Harvard College | Métodos para la detección de analitos |
| ES2952728T3 (es) | 2011-12-22 | 2023-11-03 | Harvard College | Métodos para la detección de analitos |
| EP2847700B1 (en) * | 2012-05-09 | 2022-12-07 | Koninklijke Philips N.V. | Interventional information brokering medical tracking interface |
| WO2013184754A2 (en) | 2012-06-05 | 2013-12-12 | President And Fellows Of Harvard College | Spatial sequencing of nucleic acids using dna origami probes |
| WO2014123879A1 (en) | 2013-02-05 | 2014-08-14 | Anthrogenesis Corporation | Natural killer cells from placenta |
| US10138509B2 (en) | 2013-03-12 | 2018-11-27 | President And Fellows Of Harvard College | Method for generating a three-dimensional nucleic acid containing matrix |
| RU2690935C2 (ru) | 2013-06-04 | 2019-06-06 | Президент Энд Фэллоуз Оф Харвард Коллидж | Направляемая рнк регуляция транскрипции |
| WO2016007839A1 (en) | 2014-07-11 | 2016-01-14 | President And Fellows Of Harvard College | Methods for high-throughput labelling and detection of biological features in situ using microscopy |
| JP6882282B2 (ja) | 2015-11-03 | 2021-06-02 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 三次元核酸含有マトリックスの立体撮像のための方法と装置 |
| EP4613756A3 (en) | 2016-04-25 | 2025-11-12 | President And Fellows Of Harvard College | Hybridization chain reaction methods for in situ molecular detection |
| CN105920679B (zh) * | 2016-04-26 | 2018-10-19 | 青岛大学 | 一种具有三维梯度孔结构的皮肤支架材料的制备方法 |
| EP3507364A4 (en) | 2016-08-31 | 2020-05-20 | President and Fellows of Harvard College | METHODS OF GENERATING NUCLEIC ACID SEQUENCE LIBRARIES FOR IN SITU FLUORESCENT SEQUENCING DETECTION |
| CN109923216B (zh) | 2016-08-31 | 2024-08-02 | 哈佛学院董事及会员团体 | 将生物分子的检测组合到使用荧光原位测序的单个试验的方法 |
| US11185568B2 (en) | 2017-04-14 | 2021-11-30 | President And Fellows Of Harvard College | Methods for generation of cell-derived microfilament network |
| US11718829B2 (en) | 2017-07-28 | 2023-08-08 | Breakthrough Tech Llc | Methods and compositions for manufacturing extracellular matrix |
| CN112384200A (zh) | 2018-01-30 | 2021-02-19 | 希斯托金公司 | 低氧条件下培养的细胞衍生的胞外囊泡及其用途 |
| CN112770776B (zh) | 2018-07-30 | 2025-08-19 | 瑞德库尔有限责任公司 | 用于样品处理或分析的方法和系统 |
| WO2020076976A1 (en) | 2018-10-10 | 2020-04-16 | Readcoor, Inc. | Three-dimensional spatial molecular indexing |
| CN111084788A (zh) * | 2018-10-22 | 2020-05-01 | 上海蓝盎电子科技发展有限公司 | 人工细胞间质 |
| US12077780B2 (en) | 2020-02-14 | 2024-09-03 | Allergan Sales, Llc | Conditioned medium from cells cultured under hypoxic conditions and uses thereof |
| US20220049303A1 (en) | 2020-08-17 | 2022-02-17 | Readcoor, Llc | Methods and systems for spatial mapping of genetic variants |
| WO2023030435A1 (en) | 2021-09-01 | 2023-03-09 | Shanghai Qisheng Biological Preparation Co., Ltd. | Cartilage regeneration using injectable, in situ polymerizable collagen compositions containing chondrocytes or stem cells |
| WO2023125689A1 (en) | 2021-12-28 | 2023-07-06 | Shanghai Qisheng Biological Preparation Co., Ltd. | Hyaluronic acid-collagen copolymer compositions and medical applications thereof |
| CN115006597B (zh) * | 2022-06-02 | 2024-01-19 | 上海威高医疗技术发展有限公司 | 一种口腔修复膜及其制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3949073A (en) * | 1974-11-18 | 1976-04-06 | The Board Of Trustees Of Leland Stanford Junior University | Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution |
| US4424208A (en) * | 1982-01-11 | 1984-01-03 | Collagen Corporation | Collagen implant material and method for augmenting soft tissue |
| US4582640A (en) * | 1982-03-08 | 1986-04-15 | Collagen Corporation | Injectable cross-linked collagen implant material |
| US4837285A (en) * | 1984-03-27 | 1989-06-06 | Medimatrix | Collagen matrix beads for soft tissue repair |
| US5288617A (en) * | 1984-10-31 | 1994-02-22 | Commonwealth Scientific And Industrial Research Organization | Method of producing an antigenic preparation |
| US5160490A (en) * | 1986-04-18 | 1992-11-03 | Marrow-Tech Incorporated | Three-dimensional cell and tissue culture apparatus |
| US4721096A (en) * | 1986-04-18 | 1988-01-26 | Marrow-Tech Incorporated | Process for replicating bone marrow in vitro and using the same |
| US4963489A (en) * | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
| US5032508A (en) * | 1988-09-08 | 1991-07-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
| US5266480A (en) * | 1986-04-18 | 1993-11-30 | Advanced Tissue Sciences, Inc. | Three-dimensional skin culture system |
| US5460939A (en) * | 1986-04-18 | 1995-10-24 | Advanced Tissue Sciences, Inc. | Temporary living skin replacement |
| US4803075A (en) * | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
| JPH041118Y2 (enExample) * | 1986-07-31 | 1992-01-14 | ||
| GB8708009D0 (en) * | 1987-04-03 | 1987-05-07 | Clayton Found Res | Injectable soft tissue augmentation materials |
| US5342765A (en) * | 1991-08-01 | 1994-08-30 | Occidental Chemical Corporation | Method of producing extracellular products from aerobic microorganisms |
| US5204382A (en) * | 1992-02-28 | 1993-04-20 | Collagen Corporation | Injectable ceramic compositions and methods for their preparation and use |
| US5478739A (en) * | 1992-10-23 | 1995-12-26 | Advanced Tissue Sciences, Inc. | Three-dimensional stromal cell and tissue culture system |
| US5541106A (en) * | 1993-04-05 | 1996-07-30 | Desmos, Inc. | Cell matrix stimulated attachment and hemidesmosome assembly |
| US5397352A (en) * | 1993-08-27 | 1995-03-14 | Burres; Steven | Method of recollagenation |
| US5516532A (en) * | 1994-08-05 | 1996-05-14 | Children's Medical Center Corporation | Injectable non-immunogenic cartilage and bone preparation |
-
1995
- 1995-06-06 US US08/470,101 patent/US5830708A/en not_active Expired - Lifetime
-
1996
- 1996-06-06 CA CA002223892A patent/CA2223892A1/en not_active Abandoned
- 1996-06-06 DE DE69634454T patent/DE69634454T2/de not_active Expired - Lifetime
- 1996-06-06 KR KR1019970708695A patent/KR19990022216A/ko not_active Ceased
- 1996-06-06 EP EP96921369A patent/EP0967934B1/en not_active Expired - Lifetime
- 1996-06-06 AT AT96921369T patent/ATE290350T1/de not_active IP Right Cessation
- 1996-06-06 JP JP50179097A patent/JP3709487B2/ja not_active Expired - Lifetime
- 1996-06-06 ES ES96921369T patent/ES2238076T3/es not_active Expired - Lifetime
- 1996-06-06 AU AU62609/96A patent/AU708090B2/en not_active Expired
- 1996-06-06 NZ NZ311313A patent/NZ311313A/xx unknown
- 1996-06-06 WO PCT/US1996/009482 patent/WO1996039101A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US5830708A (en) | 1998-11-03 |
| KR19990022216A (ko) | 1999-03-25 |
| JP3709487B2 (ja) | 2005-10-26 |
| AU708090B2 (en) | 1999-07-29 |
| ATE290350T1 (de) | 2005-03-15 |
| DE69634454D1 (de) | 2005-04-14 |
| AU6260996A (en) | 1996-12-24 |
| EP0967934B1 (en) | 2005-03-09 |
| EP0967934A1 (en) | 2000-01-05 |
| CA2223892A1 (en) | 1996-12-12 |
| DE69634454T2 (de) | 2006-05-11 |
| JPH11507558A (ja) | 1999-07-06 |
| EP0967934A4 (en) | 2001-11-28 |
| NZ311313A (en) | 2000-05-26 |
| WO1996039101A1 (en) | 1996-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2238076T3 (es) | Composiciones y procedimientos para matrices extracelulares secretadas de forma natural. | |
| US6284284B1 (en) | Compositions and methods for production and use of an injectable naturally secreted extracellular matrix | |
| Krishtul et al. | Processed tissue–derived extracellular matrices: tailored platforms empowering diverse therapeutic applications | |
| Beiki et al. | Fabrication of a three dimensional spongy scaffold using human Wharton's jelly derived extra cellular matrix for wound healing | |
| US7358284B2 (en) | Particulate acellular tissue matrix | |
| CN102066558B (zh) | 胞外基质组合物 | |
| EP1087756B1 (en) | Particulate acellular tissue matrix | |
| US5830507A (en) | Biotherapeutic cell-coated microspheres | |
| AU777853B2 (en) | Three-dimensional stromal tissue | |
| RU2461622C2 (ru) | Биоинженерный конструкт для имплантации ткани и способ изготовления названного биоинженерного конструкта (варианты) | |
| EP1698358A1 (en) | Transplantable biomaterial and method of preparing the same | |
| JP2001510358A (ja) | 組織修復および再構築に用いられる生重合体発泡体 | |
| AU3552099A (en) | Creation of three-dimensional tissues | |
| JPH10509080A (ja) | 細胞間マトリックス微粒子を備えた生重合体フォーム | |
| WO2001003750A1 (en) | Human naturally secreted extracellular matrix-coated device | |
| US12397085B2 (en) | Producing method of the collagen-laminin matrix for healing ulcers, burns and wounds of a human skin | |
| Kumaresan et al. | Development of Human Umbilical cord based scaffold for tissue engineering application | |
| AU668959C (en) | Biotherapeutic cell-coated microspheres | |
| Kaarthick | VETERINARY SURGERY AND RADIOLOGY | |
| Armour | Evaluation of porcine acellularized dermal matrix as a biomaterial, in vitro fibroplasia | |
| Jian et al. | Modified acellular dermal matrix for chondrocyte implantation in repairing cartilage defects of rabbits○ | |
| US20140023722A1 (en) | Neural Scaffold Biomaterial |